Navigation Links
Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
Date:2/19/2009

care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion worldwide.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to ob
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces that ... catalogue: Baby Food Eastern Europe 2014 ... Food Eastern Europe 2014" is a new report by ... in Eastern Europe , key segments, ... This report also examines trends which are currently affecting ...
(Date:8/27/2014)... YORK , Aug. 27, 2014 ... new market research report is available ... Chinese Guidebook for Application and Approval ... Regulations to Practices (2014 Edition) ... Now, Chinese regulations ...
(Date:8/27/2014)... and NINGBO, China , Aug. 27, ... Menovo Pharmaceutical Co., Ltd, ("Menovo") today announced they had ... generic pharmaceuticals, primarily targeting the United States ... Amerigen and Menovo will jointly develop products for Amerigen ... . Menovo will be responsible for manufacturing API and ...
Breaking Medicine Technology:Baby Food Eastern Europe 2014 2Baby Food Eastern Europe 2014 3Baby Food Eastern Europe 2014 4Baby Food Eastern Europe 2014 5Baby Food Eastern Europe 2014 6Baby Food Eastern Europe 2014 7Baby Food Eastern Europe 2014 8Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 5Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 6Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 7Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 8Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 9Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 10Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2
(Date:8/28/2014)... 2014 Registration is now open for ... in Holmdel, New Jersey on Sunday, October 19, 2014. ... New Jersey Vietnam Veterans’ Memorial adjacent to the Vietnam ... Arts Center. All proceeds of the event will benefit ... restoring a sense of self, restoring the family unit, ...
(Date:8/28/2014)... graduate, rising star and The Voice Season 5 contestant Brandon ... for Pepsi’s Southern Original . He’s heading to Panama City ... coach from The Voice and country music superstar Blake Shelton. Chase ... 28th at 9:00 pm at Tootsie’s at Pier Park in Panama ... Gulf Coast Jam main stage on Sunday, August 31 at 4:30 ...
(Date:8/28/2014)... 2014 ChiLiving® will host its ... NC at holistic retreat center, Om Sanctuary. This ... Katherine and Danny Dreyer, offers beginner to seasoned ... that support a lifetime of pain-free, injury-free movement ... in the heart of the Blue Ridge Mountains ...
(Date:8/28/2014)... Houston, Texas (PRWEB) August 28, 2014 ... Program. The program is a chance for regular customers ... MMAR Medical without the need for a wholesale license. ... athletics coaches, semi-professional athletic programs and others who regularly ... point. , “Whether supporting your own active lifestyle ...
(Date:8/28/2014)... Fort Worth, Texas (PRWEB) August 28, 2014 ... experiencing significant growth over the past few years. The new ... - will offer higher quality and larger office space than ... for growth. , “We are pleased about our new ... Laurenzo said. “While our suite will be double in size ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Second Annual NJ Run 2Health News:Rising Star Brandon Chase Named Finalist in Pepsi Southern Original Contest 2Health News:Join ChiRunning® & ChiWalking® Creators, Katherine and Danny Dreyer, for First-ever ChiWeekend Retreat in Asheville, NC 2Health News:Join ChiRunning® & ChiWalking® Creators, Katherine and Danny Dreyer, for First-ever ChiWeekend Retreat in Asheville, NC 3Health News:MMAR Medical Announces Customer Membership Program 2
... Do adolescents get enough exercise and eat the right ... Researchers analyzed the behavior of almost 900 11-to-15 year-olds ... and dietary risk behaviors, almost half had at least ... of the health guidelines in the study. ...
... the protein EGFR are important for the development of lung ... However, not all individuals// express the same mutant EGFR, for ... of EGFR and some have a mutation that affects the ... ,The potential of therapeutics to benefit individuals with ...
... The most recent Cochrane Review concluded antidepressants bupropion (Zyban) ... smoking and have few side-effects, but selective Serotonin reuptake ... ,Although nicotine medications are known to ... them or wants to use them. One possible alternative ...
... new report finds that less number of women aged 40 ... declining mammography rate could mean more breast cancer deaths down ... rates kept increasing during the 1990s, and scientists are disturbed ... reminded that, despite mammography being a test that's been around ...
... women who take folic acid supplements during their early pregnancy ... baby up to 40%. The Study results were published in ... ,Folic acid, a synthetic compound of a B vitamin ... neural tube disorders such as spina bifida. But its impact ...
... Scientists at UC Irvine have discovered that learning appears to ... hallmarks of Alzheimer's disease.// The finding suggests that the elderly, ... of this degenerative disease. The study appears in the Jan. ... ,This study with genetically modified mice is the first to ...
Cached Medicine News:Health News:Assessing Diet and Exercise Behaviors in Adolescents 2Health News:Mammography Saves Life-Beware Women Over 40 2Health News:Folic Acid Reduces Risk Of Cleft Lip 2Health News:Learning Slows Physical Progression of Alzheimer's Disease: Study 2
Digital Ultrasonic Diagnostic Imaging System...
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Pefakit PiCT LMWH Controls...
Calcium Chloride 0.020M - 4 ml...
Medicine Products: